ReviewNature reviews. Urology2016
Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.
Review in Nature reviews. Urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 3 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Minimally invasive treatments for benign prostatic hyperplasia in patients over 75: a systematic review.World journal of urology · 2025Pooled it
- Impact of Diabetes Mellitus on Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients: A Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Association between benign prostate hyperplasia and metabolic syndrome in men under 60 years old: a meta-analysis.The Journal of international medical research · 2019Pooled it
- Reframing Benign Prostatic Hyperplasia as a Cardiometabolic Condition: Should BPH Be Considered a Metabolic Disease?Reviews in cardiovascular medicine · 2026Article
- Efficacy and safety of 1470-nm diode laser enucleation of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis.International journal of surgery (London, England) · 2026Article
- Keratin 20 deficiency phenocopies human UAB and drives bladder fibrosis via a mechanotransduction-TGF-β axis.iScience · 2026Article
- Green chemistry for prostate health: exploring nature's toolbox against cancer, inflammation, and hyperplasia.Molecular diversity · 2026Review
- Bedside risk score for medical therapy failure in small-volume BPH: Temporal validation.BJUI compass · 2026Article
- Oxidative stress reprograms benign prostatic hyperplasia microenvironments: insights from integrative multi-omics and machine learning.Journal of translational medicine · 2026Article
- Nanomedicine for Benign Prostatic Hyperplasia: Pathological Axes and Translational Evidence.International journal of nanomedicine · 2026Review
- Predicting benign prostatic hyperplasia risks: model development and external validation based on three cohorts.Global health research and policy · 2025Article
- Association of Sarcopenic Obesity with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms: A Nationwide Cross-sectional Study.European urology open science · 2025Article
- Testosterone and Lower Urinary Tract Symptoms: A Narrative Review.Current urology reports · 2025Review
- The association between arthritis and the risk of lower urinary tract symptoms suggestive of benign prostate hyperplasia: evidence from the China Health and Retirement Longitudinal Study (CHARLS).Scientific reports · 2025Article
- Global, regional, and national lifetime risks of developing benign prostatic hyperplasia in men aged over 40: a population-based cross-sectional study from 1990 to 2021.Tropical medicine and health · 2025Article
- Article
- Incidence and predictors of transurethral resection of prostate in men with and without type 2 diabetes: the Fremantle Diabetes Study Phase I.Internal medicine journal · 2025Article
- Cross-sectional study on the association between serum uric acid levels and the risk of benign prostatic hyperplasia.BMJ open · 2025Article
- SMC Abca1 and Abcg1 Deficiency Enhances Urinary Bladder Distension but Not Atherosclerosis.Circulation research · 2025Article
- Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiological studies have shown that age is the principal unmodifiable risk factor of lower urinary tract symptoms (LUTS). Until the past decade, the process of lower urinary tract ageing was, therefore, considered unmodifiable - as ageing per se. However, the traditional dogma that BPH-related LUTS (BPH-LUTS) is an immutable consequence of old age is no longer acceptable. Results from multiple preclinical and clinical studies indicate that several modifiable, age-related metabolic aberrations (metabolic syndrome, obesity, dyslipidaemia, diabetes) are important determinants in both the development and the progression of BPH-LUTS. Metabolic syndrome and its related comorbidities, such as sex steroid alterations and low-grade inflammation, have been related to BPH-LUTS development and progression. With the correct treatment and recommended lifestyle changes, many individuals with metabolic syndrome might be able to prevent or delay the onset of metabolic-syndrome-related complications; however, whether promoting healthier lifestyles can really alter a man's propensity to develop BPH-LUTS remains to be clarified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.